Crossmark Global Holdings, Inc. Supernus Pharmaceuticals, Inc. Transaction History

Crossmark Global Holdings, Inc.

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Jan 10, 2022	SELL	$26.37 - $34.22 $476,769 - $618,697	-18,080 Closed	0 $0
Q3 2021 Oct 21, 2021	BUY	$23.54 - $31.39 $425,603 - $567,531	18,080 New	18,080 $482,000
Q3 2021 Oct 13, 2021	SELL	$23.54 - $31.39 $427,015 - $569,414	-18,140 Closed	0 $0
Q2 2021 Jul 21, 2021	BUY	$26.72 - $33.19 $1,068 - $1,327	40 Added 0.22%	18,140 $559,000
Q1 2021 Apr 15, 2021	BUY	$24.15 - $31.45 $38,157 - $49,691	1,580 Added 9.56%	18,100 $474,000
Q4 2020 Jan 14, 2021	BUY	$17.7 - $25.81 $292,404 - $426,381	16,520 New	16,520 $416,000
Q4 2019 Feb 06, 2020	SELL	$19.93 - $29.13 $249,722 - $364,998	-12,530 Closed	0 $0
Q3 2019 Oct 09, 2019	SELL	$25.47 - $33.37 $4,075 - $5,339	-160 Reduced 1.26%	12,530 $344,000
Q2 2019 Jul 09, 2019	SELL	$29.96 - $38.87 $27,862 - $36,149	-930 Reduced 6.83%	12,690 $420,000
Q1 2019 May 02, 2019	SELL	$32.77 - $41.99 $1,966 - $2,519	-60 Reduced 0.44%	13,620 $477,000
Q4 2018 Jan 31, 2019	SELL	$30.84 - $49.51 $110,407 - $177,245	-3,580 Reduced 20.74%	13,680 $454,000
Q3 2018 Nov 08, 2018	SELL	$42.7 - $56.55 $30,744 - $40,716	-720 Reduced 4.0%	17,260 $869,000
Q2 2018 Jul 31, 2018	BUY	$44.1 - $59.85 $33,516 - $45,486	760 Added 4.41%	17,980 $1.08 Million
Q1 2018 Apr 16, 2018	SELL	$37.15 - $46.9 $61,297 - $77,385	-1,650 Reduced 8.74%	17,220 $789,000
Q4 2017 Feb 05, 2018	SELL	$36.4 - $42.6 $93,912 - $109,908	-2,580 Reduced 12.03%	18,870 $752,000
Q3 2016 Oct 25, 2017	BUY	N/A	21,450	21,450 $858,000

283

60.6M

27.7K

11.3K

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $2.06B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

Get notified when there are updates to the investment portfolio of Crossmark Global Holdings, Inc., based on Form 13F filings with the SEC.

Stay updated on Crossmark Global Holdings, Inc. with notifications on news.